Statins is HMG-CoA inhibitors which used for decreasing plasma cholesterol levels and preventing coronary artery disease. Preclinical and clinical studies showed that statin could decrease the risk of cancer. This study was performed to evaluate the cytotoxic activity of simvastatin on T47D breast cancer cell lines and its effect in cyclin D 1 expression and apoptosis. This was quasi experiment using post test with non-equivalent control group design. Simvastatin cytotoxic activity was evaluated using MTT assay. Furthermore, the effect of simvastatin on cyclin D 1 expression and apoptosis were evaluated using flow cytometry using antibody monoclonal anti-cyclin D 1 and annexin V-Pi, respectively. The results showed that simvastatin had cytotoxic activity on T47D breast cancer cell lines with an IC 50 value of 25.25 ± 1.61 µg/mL. Moreover, simvastatin in concentration range from 6.31 to 50.5 µg/mL decreased the cyclin D1 expression with an EC 50 value of 18.96±4.42 µg/mL and induced apoptosis with an EC 50 value of 26.96 ± 6.05 µg/mL. In conclusion, simvastatin inhibits T47D breast cancer cell growth through reduction of cyclin D 1 expression and induction of apoptosis.
INTRODUCTION
Cancer can be defined as the rapid growth of body cells cause disorders thus growth beyond the limits of necessity and then invade and spread to other parts of the body. Breast cancer is one of the most common cancers that cause death in women in the world. In 2013 Ministry of Health, Republic of Indonesia reported that the prevalence of breast cancer was the second highest in Indonesia, approximately 0.5% of total population, with the highest prevalence in Yogyakarta Special Region (2.4%). 1 Statin (HMG-CoA Inhibitors) is drugs used for decreasing cholesterol level and prevent heart coroner disease. 2 In Indonesia, 82.3% patients with hypercholesterolemia still use statin as first choice drug with the most frequently used is simvastatin (42.8%) followed by rosuvastatin (27.9%) and atorvastatin (19.2%) . 3 Statin use is associated with 20% risk reduction of cancer. Statin have protective effect on cancer survivors therapy for more than 4 years. 4 Cohort study found that using simvastatin in patients diagnosed with breast cancer, could reduce the death rate of breast cancer. 5 Furthermore, the statins such as fluvastatin, atorvastatin and simvastatin can inhibit cell proliferation associated with decreasing synthesis of DNA and cell cycle arrest in G 1 and G 2 /M by increasing the expression of p53 and p21 proteins and induces cell death with oxidative stress. 6, 7 Simvastatin could also induce antiproliferative effects and increase expression of caspase 3 in order to stimulate apoptosis. 8, 9 This study was conducted to prove the cytotoxicity of simvastatin against T47D breast cancer cell lines and its effect on cyclin D 1 expression and apoptosis.
MATERIALS AND METHODS

Materials
Simvastatin, 4-(2-hydrocyethyl)-piperazine-ethane) sulphonic acid (HEPES), RPMI 1640, fetal bovine serum (FBS) 10%, amphotericin B, penicillin-streptomycin, and trypsin were obtained from Sigma-Aldrich 
Cytotoxic activity assay
The T47D breast cancer cell lines at 1 x 10 5 /mL were plated in 96 well microplate with 100 µL each well and incubated for 24 hours in starvated media. One hundred µL of simvastatin solution in concentration 50; 25; 12.5; 6.25; 3.125; and 1.5625 µg/mL were added in triplicate and then incubated for 24 hours. The media in each well was changed with 100 μL new media and 10 μL MTT reagent was added in each well and then incubated for 4-6 hours in a CO 2 incubator at 37°C. Followed after incubation, 100 µL SDS in HCl 10% was added in each well and incubated at room temperature for 12 hours. The absorbance of each well was recorded using ELISA reader at λ of 595 nm. The absorbance of each well was used to calculate the percentages of proliferation inhibition by comparing with the control cells without any compounds. The concentration inhibiting 50% (IC 50 ) of the cell lines was determined by probit analysis.
Expression of cyclin D 1 assay
The T47D breast cancer cell lines were cultured in 6 well plates at 5x10 5 
Apoptosis induction assay
The T47D breast cancer cell lines were cultured at 5x10 5 in 6 well plates. Each well was added with 2000 µL from each concentration series of simvastatin 0; 6.31; 12.62; 25.25 and 50.48 µg/mL and doxorubicin 0.15 µg/mL. Solutions were prepared using incubation buffer 10 mM Hepes/NaOH pH 7.4; 140 mM NaCl and 5 mM CaCl2. Labeling solution for sample consisting of 15 to 30 μL of annexin V plus 1.5 mL of incubation buffer and 30 µL of PI. Incubation cells were placed at the dark room for 10-15 minutes at a temperature of 15-25°C. Apoptosis was analyzed using FACS-Calibur program to obtain distribution of the survived cell, apoptotic and necrotized cell on all treatment group. The apoptosis induction activity was assessed on the concentration inducing 50% apoptosis (EC 50 ) which determined by probit analysis.
Statistical analysis
Data of IC 50 an EC 50 were presented as mean ± SD. Data of cyclin D1 expression and apoptosis induction were presented as percentage and compared using analysis of variance (ANOVA) followed by post hoc Bonferroni or Tamhane. A p value <0.05 was considered as statistically significant.
RESULTS
Cytotoxic activity assay
The inhibitory concentration 50% (IC 50 ) of simvastatin and doxorubicin on T47D breast cancer cell lines were 25.25±1.61 and 0.15±0.016 µg/mL, respectively (TABLE 1) . These results showed that simvastatin had cytotoxic activity on T47D breast cancer cell lines, although its activity was lower than that doxorubicin as positive control (p<0.05). 
Expression of cyclin D 1 assay
The cyclin D 1 expression of T47D breast cancer cell line after incubation with simvastatin is presented in 
Apoptosis induction assay
The apoptosis of T47D breast cancer cell line after incubation with simvastatin is presented in FIGURE 2. Lower left showed live cells population, lower right showed apoptotic cells, and upper right showed necrotic cells. 
DISCUSSION
Cytotoxic activity of simvastatin
The T47D breast cancer cell lines was used in this study due to its high homogeneity and its simplicity replaceable with frozen stock contamination observed. Therefore these cells are often used for in vitro cancer studies. 10 The results showed that incubation with simvastatin at concentrations from 50 to 1.5625 µg/mL (119.45-3.73 µM) for 24 hours inhibited T47D cell lines proliferation. This finding was consistent with other in vitro studies conducted by some authors. Lee et al. 11 showed that incubation with simvastatin at concentrations from 0 to 500 µM (0-209.3 µg/mL) for 24 and 48 hours inhibited the bile duct cancer cells proliferation. The incubation with simvastatin at concentration from 15 to 120 µM (6.27 to 50.22 µg/mL) for 24 and 28 also inhibited lung cancer A549 cells proliferation. 12, 13 Furthermore, Huang et al. 14 reported that incubation with simvastatin at concentration from 2 to 16 µM for 24-72 hours inhibited the HepG2 and Huh7 cell line growth. The proliferation inhibition of ECC-1 and Ishikawa cell lines were also observed after incubation with simvastatin at concentration from 0.01 to 50 µM (0.0041 to 20.92 µg/mL). 15 According to American National Cancer Institute (NCI), a compound is considered to have cytotoxic effect on cancer cell lines if its IC 50 lower than 50 µg/mL. 16 Furthermore, a compound could be classified as a very active, active and moderate potential anticancer compound if they have IC 50 value < 5, 5-10 and 11-30 µg/mL, respectively. 17 Based on this criteria, simvastatin with an IC 50 value of 25.25±1.61 µg/mL could be classified as a moderate potential anticancer compound. The IC 50 of statin group on several cancer cell lines in different incubation period has been reported in the previous studies. The IC 50 of simvastatin on MDM-231, SKBr3 and MCF7 cancerous cell varied from 1.26 to 91 µM, 18 whereas on A549 cancerous cells was 45 µM and on HeLa cell line was 9.14 µM. 12, 19 Other statin drug, fluvastatin also showed cytotoxic effect against C6 glioma cancer cells. 18 In addition, atorvastatin was active against NCI-H292 cancer cells with an IC 50 value of 5.54 µg/mL 20 and lovastatin was active against MDAMB468 and MDAMB231 cancer cells with IC 50 values of 8 μg/mL and 5 μg/mL, respectively.
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Effect of simvastatin on cyclin D 1 expression
Simvastatin decreased cyclin D 1 expression of T47D breast cancer cell lines in a concentration-dependent manner (TABLE  2) . This finding was similar with study conducted by Liang et al. 22 which showed that simvastatin at concentration range from 12. . 23 Another study reported that simvastatin induced apoptosis in the HepG2 and Huh7 cancer cell lines and its activity was accompanied by inhibition of CDK and cyclin D 1 , whereas CDK inhibitors p19 and p27 were enhanced. 24 Other statins such as lovastatin also could affect the cell cycle by decreased cyclin D1-CDK 4 expression and increased p21 WAF1/CIP1 expression on MCF-7 cells.
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Apoptosis induction activity of simvastatin
Simvastatin increased cells apoptosis in a concentration-dependent manner. This finding indicated that simvastatin induced apoptosis in T47D breast cancer cell lines. This finding similar with previous studies conducted by some authors. Gopalan et al. 25 demonstrated that incubation with simvastatin at concentration range from 0.625-5.0 µM for three days induced apoptosis of MCF7 and MDA-MB-231 cancer cell line via activation of JNK/CHOP/DR5 signaling pathway. Ghosh-Choudury et al. 26 also demonstrated that simvastatin attenuated the antiapoptotic Bcl XL expression and induced depression of phosphatase and tensin homologous (PTEN) expression through NFκB to inhibit breast cancer growth. In addition, Koyuturk et al. 27 reported that simvastatin induced apoptosis through involvement of JNK in breast cancer cells independent of their ER or p53 expression status. Simvastatin also suppressed PI3K/Akt/mTOR pathway by enhancing PTEN expression and by further sequentially dephosphorylating downstream cascades including Akt, mTOR, p70S6K, S6RP and 4E-BP1. Furthermore, simvastatin inhibited MAPK/ERK pathway by dephosphorylating sequential cascades such as c-Raf, MEK1/2 and ERK1/2.
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CONCLUSION
Simvastatin shows cytotoxic activity on T47D breast cancer cell lines with an IC 50 value of 25.25 µg/mL. Furthermore, simvastatin decrease cyclin D1 expression with an EC 50 value of 18.96 µg/mL, and induce apoptosis with an EC 50 value of 26.96 µg/mL.
